cas 1589082-26-7|| where to buy (S)-2-(piperazin-2-yl)acetonitrile

Название продукции:(S)-2-(piperazin-2-yl)acetonitrile

IUPAC Name:2-[(2S)-piperazin-2-yl]acetonitrile

Упаковочная единица	Доступно для заказа	Цена ($)	Количество
CM325414-1g	in stock	ǕǕ

Только для использования в НИОКР..

Форма запроса

Химическое название

Номер CAS

Количество*

Необходимые спецификации*
(% пробы, категория материала и т.д.)

Контактное лицо*

Электронная почта*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 1589082-26-7 regularly via the above email.

Дополнительные примечания

Verification code*

refresh

: Номер CAS:1589082-26-7; Молекулярная формула:C6H11N3; Точка плавления:-; Smiles-код:N#CC[C@@H]1NCCNC1; Плотность:

: Номер в каталоге:CM325414; Молекулярная масса:125.18; Точка кипения:; Номер Mdl:; Хранение:

: Piperazines; Piperazine is an organic compound consisting of a six-membered ring containing two nitrogen atoms in opposite positions in the ring. The chemical formula of piperazine is C4H10N2, and it is an important pharmaceutical intermediate. Pyrimidines and piperazines are known to be the backbone of many bulk compounds and important core structures for approved drugs; studies have shown that combining a pyridine ring with a piperazine moiety within a single structural framework enhances biological activity.

: Adagrasib; Jan. 10, 2024, EC approves KRAZATI (adagrasib) as a targeted treatment option for patients with advanced non-small cell lung cancer (NSCLC) with a KRAS G12C mutation.
Adagrasib is an orally available, potent, irreversible, small molecule inhibitor of KRAS G12C mutant isoform for the treatment of solid tumours harbouring KRAS G12C oncogenic driver mutation. Adagrasib covalently binds to the mutant cysteine in KRAS G12C and locks the mutant KRAS protein in its inactive state, thereby preventing downstream signalling without affecting wild-type KRAS protein.